Lada Mitchell

6.2k citations

35 papers · 4.5k indexed · 2 hit papers · h-index 14

Impact in

Cardiology and Cardiovascular Medicine top 1%
- Blood Pressure and Hypertension Studies
- Renin-Angiotensin System Studies
- Heart Rate Variability and Autonomic Control
Endocrinology, Diabetes and Metabolism top 1%
- Hormonal Regulation and Hypertension

Papers in ⓘ

Oncology 18
- HER2/EGFR in Cancer Research 9
- Cancer Treatment and Pharmacology 5
- Colorectal Cancer Treatments and Studies 5
- Peptidase Inhibition and Analysis 5
Pulmonary and Respiratory Medicine 13
- Pulmonary Hypertension Research and Treatments 4
- Lung Cancer Treatments and Mutations 4

Co-authors: Francis Plat (2 shared papers)Sverre E. Kjeldsen (2 shared papers)Tsushung A. Hua (2 shared papers)Michael A. Weber (2 shared papers)Beverly A. Smith (2 shared papers)Stevo Julius (2 shared papers)Gordon T. McInnes (2 shared papers)Alberto Zanchetti (2 shared papers)
Journals: Journal of Clinical Oncology (12 papers)Annals of Oncology (4 papers)Pharmaceutical Statistics (2 papers)The Oncologist (2 papers)Cardiology and Therapy (2 papers)
Partner nations: Switzerland Spain United Kingdom

In The Last Decade

Lada Mitchell

33 papers receiving 4.2k citations

Hit Papers

align trajectories log scale

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial 2004 · 1.8k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2004 The Lancet
2003 Journal of the Royal Statistical Society Series D (The Statistician)

Peers

Countries citing papers authored by Lada Mitchell

Since Specialization

Citations

This map shows the geographic impact of Lada Mitchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lada Mitchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lada Mitchell more than expected).

Fields of papers citing papers by Lada Mitchell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lada Mitchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lada Mitchell. The network helps show where Lada Mitchell may publish in the future.

Co-authors

The 25 scholars most cited alongside Lada Mitchell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lada Mitchell Line = papers co-authored together Lada Mitchell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial The Lancet ·Stevo Julius, Sverre E. Kjeldsen, Michael A. Weber, Hans R. Brunner, Steffan Ekman, Lennart Hansson, Tsushung A. Hua, John H. Laragh, Gordon T. McInnes, Lada Mitchell, Francis Plat, Anthony Schork, Beverly A. Smith, Alberto Zanchetti Hit paper breakdown →	2004	1845
2	Applied Multivariate Statistics for the Social Sciences Journal of the Royal Statistical Society Series D (The Statistician) ·Lada Mitchell Hit paper breakdown →	2003	854
3	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial The Lancet ·Michael A. Weber, Stevo Julius, Sverre E. Kjeldsen, Hans R. Brunner, Steffan Ekman, Lennart Hansson, Tsushung A. Hua, John H. Laragh, Gordon T. McInnes, Lada Mitchell, Francis Plat, M. Anthony Schork, Beverly A. Smith, Alberto Zanchetti	2004	428
4	Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089) Journal of Clinical Oncology ·Fabrice Barlési, Arnaud Scherpereel, Achim Rittmeyer, Antonio Pazzola, Neus Ferrer Tur, Joo-Hang Kim, Myung‐Ju Ahn, Joachim G.J.V. Aerts, В. А. Горбунова, Anders Vikström, Elaine K. Wong, Pablo Ernesto Pérez, Lada Mitchell, Harry J.M. Groen	2013	233
5	Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study European Journal of Cancer ·Reinhard Dummer, Simone M. Goldinger, Christian P. Turtschi, N. Eggmann, Olivier Michielin, Lada Mitchell, L. Véronèse, Paul R. Hilfiker, Lea Felderer, Jeannine D. Rinderknecht	2013	230
6	Generalized, Linear, and Mixed Models Journal of the Royal Statistical Society Series D (The Statistician) ·Lada Mitchell	2003	216
7	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study The Lancet Oncology ·James Larkin, Michele Del Vecchio, Paolo A. Ascierto, Ivana Krajsová, Jacob Schachter, Bart Neyns, Enrique Espinosa, Claus Garbe, Vanna Chiarion‐Sileni, Helen Gogas, Wilson H. Miller, Mario Mandalà, Geke A.P. Hospers, Ana Arance, Paola Queirolo, Axel Hauschild, Michael P. Brown, Lada Mitchell, L. Véronèse, Christian U. Blank	2014	193
8	Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials The Oncologist ·Herbert I. Hurwitz, Niall C. Tebbutt, Fairooz F. Kabbinavar, Bruce J. Giantonio, Zhong-Zhen Guan, Lada Mitchell, Daniel Waterkamp, Josep Tabernero	2013	176
9	An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. Journal of Clinical Oncology ·Reinhard Dummer, Jeannine D. Rinderknecht, Simone M. Goldinger, María E. Fernández, Lada Mitchell, M L Veronese, S. Nick, Paul R. Hilfiker, Sharon Gobbi	2011	48
10	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer The Oncologist ·Miguel Martín, А. Н. Махсон, Joseph Gligorov, Mikhail Lichinitser, Aňa Lluch, Semiglazov Vf, Nana Scotto, Lada Mitchell, Sergei Tjulandin	2012	40
11	Mammary tumors in dogs: survey of clinical and pathological characteristics. PubMed ·Lada Mitchell, De la Iglesia Fa, Wenkoff Ms, Van Dreumel Aa, George Lumb	1974	29
12	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). Journal of Clinical Oncology ·Josep Tabernero, Emily Chan, José Baselga, Jean‐Yves Blay, Ian Chau, David M. Hyman, Noopur Raje, Juergen Wolf, Florin Sirzén, Maria Luisa Veronese, Lada Mitchell, Manuel Hidalgo	2014	24
13	VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). Journal of Clinical Oncology ·David M. Hyman, Jean‐Yves Blay, Ian Chau, Noopur Raje, Maria Elena Elez Fernandez, Juergen Wolf, Florin Sirzén, Maria Luisa Veronese, Lada Mitchell, Igor Puzanov, José Baselga	2014	17
14	An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. Journal of Clinical Oncology ·James Larkin, Paola Queirolo, Ana Arance, Michael P. Brown, Axel Hauschild, Michele Del Vecchio, Grant A. McArthur, Bart Neyns, Jürgen C. Becker, Johan Hansson, David Hogg, Paolo A. Ascierto, Carmen Loquai, Enrique Espinosa, Claus Garbe, Poulam M. Patel, Jacob Schachter, Lada Mitchell, Maria Luisa Veronese, Christian U. Blank	2012	13
15	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS) Lung Cancer ·Egbert F. Smit, Yi‐Long Wu, Radj Gervais, Caicun Zhou, Enriqueta Felip, Jifeng Feng, Salih Zeki Güçlü, Mathias Hoiczyk, Elena Dorokhova, Ulrich Freudensprung, Susan Grange, Pablo Diego Perez-Moreno, Lada Mitchell, Martin Reck	2016	12
16	Open-Label Pilot Study of Vemurafenib in Previously Treated Metastatic Melanoma (MM) Patients (PTS) with Symptomatic Brain Metastases (BM) Annals of Oncology ·Reinhard Dummer, Simone M. Goldinger, Christian P. Turtschi, N. Eggmann, Olivier Michielin, Lada Mitchell, L. Véronèse, Paul R. Hilfiker, Jeannine D. Rinderknecht	2012	12
17	Lercanidipine vs lacidipine in isolated systolic hypertension Journal of Human Hypertension ·M.W. Millar‐Craig, B Shaffu, Anne Greenough, Lada Mitchell, Chris J. McDonald	2003	11
18	Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension ERJ Open Research ·Gerry Coghlan, Seán Gaine, Richard N. Channick, Kelly Chin, Camille Du Roure, J. Simon R. Gibbs, Marius M. Hoeper, Iréne Lang, Stephen C. Mathai, Vallerie V. McLaughlin, Lada Mitchell, Gérald Simonneau, Olivier Sitbon, Victor F. Tapson, Nazzareno Galiè	2022	11
19	A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). Journal of Clinical Oncology ·Edith A. Perez, José Manuel López-Vega, Lucia Del Mastro, Thierry Petit, Lada Mitchell, C. Pelizon, Michael Andersson	2012	11
20	Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. Journal of Clinical Oncology ·Jean‐Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Thomas Jouary, Laurent Mortier, Nicole Basset‐Séguin, Paolo A. Ascierto, Johan Hansson, Lada Mitchell, M Starnawski, Axel Hauschild	2013	11

About Lada Mitchell

Lada Mitchell is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Statistics and Probability, having authored 35 papers that have together received 4.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (9 papers), Melanoma and MAPK Pathways (6 papers), Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Peptidase Inhibition and Analysis (5 papers), Pulmonary Hypertension Research and Treatments (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (2.1k citations), Endocrinology, Diabetes and Metabolism (1.1k citations), Oncology (799 citations), Family Practice (64 citations) and Geriatrics and Gerontology (103 citations). Lada Mitchell has collaborated with scholars based in Switzerland, Spain and United Kingdom. Frequent co-authors include Francis Plat, Sverre E. Kjeldsen, Tsushung A. Hua, Michael A. Weber, Beverly A. Smith, Stevo Julius, Gordon T. McInnes, Alberto Zanchetti, John H. Laragh and Steffan Ekman. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Pharmaceutical Statistics, The Oncologist and Cardiology and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact